Author： Yong Pierre L. Bigman Cabral
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.32, Iss.12, 2009-12, pp. : 1147-1157
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Black-box warning messages differ between FDA, lay media
Reactions Weekly, Vol. 1, Iss. 1282, 2009-01 ,pp. :
Access to resources
Recommend
Risk Management Policy and Black-Box Warnings: A Qualitative Analysis of US FDA Proceedings
Drug Safety, Vol. 32, Iss. 11, 2009-11 ,pp. :
The impact of Black Box Warnings
Reactions Weekly, Vol. 1, Iss. 1358, 2011-01 ,pp. :
The US FDA `Black Box' Warning for Topical Calcineurin Inhibitors: An Ongoing Controversy
Drug Safety, Vol. 31, Iss. 3, 2008-01 ,pp. :
US FDA to enhance warnings on antidepressant labelling
Reactions Weekly, Vol. 1, Iss. 1020, 2004-01 ,pp. :